The drug was found to down-regulate PD-L1 expression in UMSCC47 cancer cells cultivated under hypoxic conditions (1% O2), probably due to a down-regulation of the upstream target hypoxia-inducible factor-1α (HIF1α) [126]. The gene discussed is CD274; the disease is cancer.